M
Maryam Banikazemi
Researcher at Columbia University
Publications - 40
Citations - 5600
Maryam Banikazemi is an academic researcher from Columbia University. The author has contributed to research in topics: Fabry disease & Enzyme replacement therapy. The author has an hindex of 24, co-authored 38 publications receiving 5075 citations. Previous affiliations of Maryam Banikazemi include New York Medical College & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Maryam Banikazemi,Jan Bultas,Stephen Waldek,William R. Wilcox,Chester B. Whitley,Marie T. McDonald,Richard S. Finkel,Seymour Packman,Daniel G. Bichet,David G. Warnock,Robert J. Desnick +10 more
TL;DR: In this article, a double-blind, placebo-controlled trial was conducted to see whether agalsidase beta delayed the onset of a composite clinical outcome of renal, cardiovascular, and cerebrovascular events and death in patients with advanced Fabry disease.
Journal Article
Agalsidase-Beta Therapy for Advanced Fabry Disease
Maryam Banikazemi,Jan Bultas,Stephen Waldek,William R. Wilcox,Chester B. Whitley,Marie T. McDonald,Richard S. Finkel,Seymour Packman,Daniel G. Bichet,David G. Warnock,Robert J. Desnick +10 more
TL;DR: The objective was to evaluate the effect of agalsidase beta on disease progression by a time-to-event analysis of renal, cerebrovascular, and cardiac events or death in patients with advanced Fabry disease in a placebo-controlled trial.
Journal ArticleDOI
Females with Fabry disease frequently have major organ involvement : Lessons from the Fabry Registry
William R. Wilcox,William R. Wilcox,João Paulo Oliveira,Robert J. Hopkin,Alberto Ortiz,Maryam Banikazemi,Ulla Feldt-Rasmussen,Katherine B. Sims,Stephen Waldek,Gregory M. Pastores,Philip Lee,Christine M. Eng,László Maródi,Kevin E. Stanford,Frank Breunig,Christoph Wanner,David G. Warnock,Roberta Lemay,Dominique P. Germain +18 more
TL;DR: Quality of life (QoL), as measured by the SF-36((R)) survey, was impaired at a later age than in males, but both genders experience significantly impaired QoL from the third decade of life onward, Thus, females with FD have a significant risk for major organ involvement and decreased QOL.
Journal ArticleDOI
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Dominique P. Germain,Stephen Waldek,Maryam Banikazemi,Maryam Banikazemi,David A. Bushinsky,Joel Charrow,Robert J. Desnick,Philip J. Lee,Thomas W. Loew,Anouk C. Vedder,Rekha Abichandani,William R. Wilcox,Nathalie Guffon +12 more
TL;DR: Long-term agalsidase beta therapy stabilizes renal function in patients without renal involvement at baseline, maintains reduction of plasma GL-3, and sustainsGL-3 clearance in capillary endothelial cells and multiple renal cell types.
Journal ArticleDOI
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.
Christine M. Eng,Maryam Banikazemi,Ronald E. Gordon,Martin E. Goldman,Robert G. Phelps,Leona Kim,Alan Gass,Jonathan A. Winston,Steven Dikman,John T. Fallon,Scott E. Brodie,Charles B. Stacy,Davendra Mehta,Rosaleen Parsons,Karen I. Norton,Michael O'Callaghan,Robert J. Desnick +16 more
TL;DR: A single-center, open-label, dose-ranging study of r-halphaGalA treatment in 15 patients, each of whom received five infusions at one of five dose regimens provides the basis for a phase 3 trial of enzyme-replacement therapy for Fabry disease.